We are proud to participate in a newly established program training the cardiovascular scientists of tomorrow: The English-language MSc Medical Sciences – Cardiovascular Research is a 1-year program, combining taught (first term) and project research (second term) content. It is dedicated to more…
Epigenetic modulators have been proposed as promising new drug targets to treat adverse remodeling in heart failure. Here, we evaluated the potential of 4 epigenetic drugs, including the pan-BRD (bromodomain-containing protein) inhibitor bromosporine, the BET (bromodomain and extraterminal) inhibitor JQ1, more…
MR antagonists have proven to be highly efficient in patients with heart failure and reduced ejection fraction, and they are a cornerstone of contemporary therapy. In the past decade, a series of experimental studies using models with cell type–specific MRs uncovered the more…
